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ABSTRACT 
Introduction 
Immunotherapeutic agents against amyloid β are associated with adverse events, including 
amyloid-related imaging abnormalities with edema and effusion (ARIA-E). Recently an MRI 
rating scale was developed for ARIA-E detection and classification. The aim of this study was 
to validate the use of this rating scale in a larger patient group with multiple raters. 
 
Methods 
MRI scans of 75 patients (29 with known ARIA-E and 46 control subjects) were analyzed by 
5 neuroradiologists with different degrees of expertise, according to the ARIA-E rating scale. 
For each patient we included a baseline and a follow-up fluid attenuated inversion recovery 
(FLAIR) image. Inter-rater agreement was calculated using intraclass correlation coefficient 
(ICC).  
 
Results  
On average 4.1% of the ARIA-E cases were missed. We observed a high inter-rater 
agreement for scores of sulcal hyperintensity (ICC=0.915; 95% CI, 85-95) and for the 
combined scores of the two ARIA-E findings, parenchymal and sulcal hyperintensity 
(ICC=0.878; 95% CI, 79–93). A slightly lower agreement for parenchymal hyperintensity 
(ICC=0.678; 95% CI, 51-81) was noted. 
 
Conclusion 
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The ARIA-E rating scale is a simple tool to evaluate the extent of ARIA-E in patients 
recruited into Aβ-lowering therapeutic trials. It shows high inter-rater agreement among raters 
with different degrees of expertise.  
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Introduction  
 
Alzheimer’s disease (AD) is a neurodegenerative disease with an increasing prevalence 
worldwide having a significant socio-economic impact.1, 2 MRI is one of the most relevant 
diagnostic tools in the diagnosis of dementia and has been included into current diagnostic 
criteria.3 Imaging findings include the demonstration of certain atrophy patterns and the 
detection of vascular (co) morbidity supporting the clinical diagnosis of AD or other diseases 
associated with dementia.4 
 
Advances in understanding the molecular background of AD pathology strongly support the 
amyloid cascade hypothesis claiming amyloid β (Aβ) as the main cause for neuronal death 
and dysfunction.5, 6 This dysregulated Aβ metabolism and its pathophysiological importance 
have led to the development of numerous therapeutic approaches to find potential disease-
modifying agents targeting Aβ such as active and passive immunotherapy.
5, 7, 8
 Due to the 
nature of AD, patients are often incapable of signaling adverse effects of these new 
therapeutic strategies. Consequently, the adverse effects of these new therapies often escape 
clinical detection. Precise monitoring by other means than clinical observation like MRI have 
become pivotal tools for detecting adverse events in AD trials. Therefore, neuroradiological 
monitoring plays an important role in therapeutic trials in AD.  
 
MRI is able to identify so-called amyloid-related imaging abnormalities (ARIA) such as 
cerebral microbleeds and superficial hemosiderosis deposits, designated as ARIA-
Hemosiderin (ARIA-H). In addition to these findings related to hemosiderin, MRI 
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hyperintensities indicative of edema and effusion have been described and named ARIA-
Edema and Effusion (ARIA-E).
9
 In ARIA-E, three different imaging features can be 
discerned: parenchymal hyperintensity (PH), sulcal hyperintensity (SH) and gyral swelling 
(SW).
9, 10
 In a minority of cases, these abnormalities were symptomatic primarily associated 
with headache, confusion, vomiting, or gait disturbance.9, 11 ARIA-E has been identified most 
frequently during treatment with amyloid-lowering drugs, especially immunotherapy, but can 
also occur spontaneously, particularly in patients presenting with cerebral amyloid 
angiopathy.9, 12 The clinical consequences of these radiological findings are still unclear; 
ARIA-E currently remains largely a radiological construct.  
 
For clinical and research purposes, mentioned above, it is imperative to have a robust and 
validated radiological scoring system that enables the correct radiological classification and 
grading of ARIA-E, at the time of diagnosis as well as during the treatment. Such a 
radiological scoring system could assist in the titration of drugs and duration of treatment. As 
these imaging abnormalities are clinically undetectable in most cases
9, 13
 an MRI scale could 
be a valuable monitoring tool for the detection of ARIA-E events.  
 
Recently, we proposed a rating scale for ARIA-E, which consists of a simple five-point 
severity rating for each region affected. Six brain areas used for this rating are the same used 
on the Age-Related White Matter Changes rating scale (ARWMC)
14
 because all of these 
regions can be also affected by ARIA-E. Our initial assessment showed promising inter-rater 
agreement between two experienced raters in a small sample size (n=10) of ARIA-E 
patients.15 So far this scale has not been tested in a group of raters with a more varying neuro-
radiological experience and who have not been involved in the scale development. Further 
testing using multiple raters in a larger dataset was necessary to validate the results from our 
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initial pilot study; this is mandatory for any rating scale before it can be used with confidence 
in clinical practice.  
 
The aim of this new study was to validate the use of this novel ARIA-E MRI rating scale in a 
larger patient group with multiple raters to establish the clinical applicability of the ARIA 
rating scale. 
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Methods 
 
Patient Population 
All patients included in this study participated in a phase II multicenter, randomized, double-
blinded, placebo-controlled, multiple ascending-dose study of bapineuzumab, a humanized 
anti-amyloid-beta (Aβ) antibody. The study was conducted to evaluate the safety and efficacy 
of bapineuzumab in 234 patients with mild to moderate AD, with an age range from 50 to 85 
years. Patients were randomly assigned to receive placebo or ascending doses (0.15 mg/kg, 
0.5mg/kg, 1.0 mg/kg and 2.0 mg/kg) of intravenous bapineuzumab every 13 weeks with up to 
6 infusions during 18 months.13, 16 
Additional inclusion criteria were a mini-mental state examination (MMSE) score of 16-26, 
where a 16-21 MMSE score was categorized as low and a 22-26 score was high.11 
 
Safety scans were performed approximately 6 weeks after each infusion starting at baseline 
and continuing up to week 71. Imaging included axial FLAIR sequences to detect ARIA-E. 
MRI was performed on 1.5 T scanners with 5 mm sections obtained in a 2D mode with 1 mm 
in-plane resolution, as described previously.16 After study completion, each MRI was re-read 
centrally by 2 radiologists who identified the presence of ARIA-E in consensus.
13
 
 
For the evaluation sample, we selected 75 patients from the abovementioned patient group 
with mild to moderate AD. This included all 29 patients with ARIA-E during the 
bapineuzumab phase-2 program. Patients were not selected on severity or otherwise to avoid 
the possible impact of selection bias. The majority of ARIA-E cases were first detected during 
the study and a minority of ARIA-E was first detected after rereading the MRI’s 
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(retrospective analysis). For comparison, we also selected 46 cases without ARIA-E, matched 
for age, gender and disease severity. 
 
Table 1 shows a detailed summary of the demographic and baseline characteristics of the 75 
selected patients. The mean age was 67 years with slightly more females in both groups 
(overall 62%). Both ARIA-E and non-ARIA-E groups had a mean MMSE score of 21 at 
enrollment. The ApoE e4 allelic frequencies in the 2 groups were 78% in ARIA-E and 77% in 
non ARIA-E respectively.  
 
Rater selection and qualification 
Five raters were invited to participate in this study. All raters were neuroradiologists; two of 
the raters had experience in the assessment of ARIA-E and were trained using the rating scale 
(F.B., M.P.W.).
15
 The other three raters had no prior experience using this rating scale and 
they had different backgrounds in terms of qualifications and years of neuroradiological 
experience. The average experience in neuroradiology was 10 years, ranging from 4 to 25 
years. After instruction and training using an online training module, scoring was performed 
in a blinded fashion with respect to the clinical information and to the scoring of the other 
raters. 
 
ARIA-E Scoring 
Axial FLAIR scan pairs of each patient, including a baseline and follow-up scan, were 
presented to each rater digitally. At the pre-study drug baseline MRI scans, no ARIA-E was 
present. On follow-up MRI scan ARIA-E was present in 29 of the patients. The MRI rating 
scale for ARIA-E was applied to the FLAIR images using an on-line viewing tool and the 
results were documented using a digital scoring form.  
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ARIA-E Scale 
The ARIA-E rating process has been described previously [15]. Briefly, for each case of 
ARIA-E (identified by presence of PH, SH or both) twelvepreviously.
15
 The rating scale for 
ARIA-E included both the location and magnitude of presentation of parenchymal 
hyperintensities, sulcal hyperintensities and gyral swelling. ARIA-E was defined in 
accordance with the guidelines of the Alzheimer’s association research Round Table 
Workgroup, including the occurrence of either Sulcal Hyperintensity or Parenchymal 
Hyperintensity.
9,15
 Twelve brain regions are rated separately for each abnormality (PH, SH 
and SW) (Table 2). A total score is calculated by summing the individual scores from the 6 
bilateral regions: frontal lobe, parietal lobe, temporal lobe, occipital lobe, central region (basal 
ganglia, thalamus, internal and external capsules, corpus callosum, insula), and infratentorial 
region (brainstem and cerebellum). Each region is scored from 0 to 5 based on the spatial 
extension and multi-focally of the abnormality. Each item is rated on the presence of absence 
of ARIA-E abnormality (score 0=normal, score 1=monofocal ≤2 cm, score 2=multifocal 
≤2cm, score 3=any lesion >2 but <4cm, score 4=any lesion ≥ 4 cm, and score 5=entire lobe). 
For each scan, a maximum score (Range, 0 – 60) is derived by summing up the twelve 
regional scores, using the highest score in each region for each of the three types of 
abnormalities (PH, SH, SW).15 The mean and range for the total sum ARIA-E scores were 
determined for all scores given by the five raters to provide insight into the variation of 
ARIA-E MRI presentation in our population. 
 
Scale Tutorial and Image Evaluation 
Specific instructions on how to perform and grade the ARIA-E changes according to the 
rating scale were provided using a web-based instructional system. For introduction and 
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reading purposes the tutorial was designed specifically with 3 separate sections. The first 
section included a brief introduction into ARIA-E providing the theoretical background and 
image examples. The second section provided an interactive tutorial on the usage of the rating 
scale form and 4 training cases, each one with its corresponding baseline and follow-up 
images, to give the raters a reference for each type of ARIA-E abnormality and how to 
measure them. The last section was dedicated to the scoring of the data set, which was 
restricted by a password provided to each rater, and allowed interactive scoring including a 
measurement tool. Subsequently, the five neuroradiologists had full access to the 75 pair of 
scans with its corresponding electronic scoring form. All raters were fully blinded to any 
information regarding treatment and clinical presentation. 
 
Statistical Analysis 
To determine agreement between raters the intraclass correlation coefficient (ICC) was 
calculated for the combination of parenchymal hyperintensity and sulcal hyperintensity 
together (ARIA-E), followed by parenchymal hyperintensity, sulcal hyperintensity, and 
swelling separately and the combination of the 3 components. Statistical analyses were 
conducted using the Statistical Package for the Social Sciences, Version 17, for Windows 
(SPSS, Chicago, Illinois).  
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Results 
 
High agreement was observed between the raters regarding the presence or absence of ARIA-
E within individual patients. The ICC for the identification of ARIA-E in the group of patients 
with and controlswithout ARIA-E was 0.953; 95% (93-96). On average, 4.1% of the 29 cases 
of ARIA-E were missed by each of the 5 raters, an average of 1.2 patients per rater.  Three 
cases of ARIA-E were not identified by at least one rater. 
 
Individual patients presented a wide range of ARIA-E manifestations, with varying severity 
and different spatial extension. Figures 1, 2 and 3 show the average scores with ranges for 
minimum and maximum score for each patient for ARIA-E (sum of SH, PH and SW); SH, 
and PH respectively. Visual inspection showed that the ranges per patient were relatively 
small for ARIA-E scores and SH scores. Larger ranges in scoring were seen in PH scores. 
Figures 4 to 7 are examples of cases with discrepant scores. 
 
The range of the ARIA-E score among the 29 scans from the ARIA-E cases was from 1.0 to 
44.4, with a mean of 7.4. The range of parenchymal hyperintensity was 0-18.8 (mean 1.2), the 
range for sulcal hyperintensity was 0-45.4 (mean 4.0), and for swelling the range was 0-34.8 
(mean 7.2). Table 3 presents the median scores by rater. The ARIA-E sensitivity and 
specificity are shown in Table 4, with an average sensitivity of 95.6% and specificity of 
98.4%. 
 
Inter-rater agreement (ICC) for sulcal hyperintensity was 0.92 (95% CI 0.85-0.95) and for the 
combined scores of two ARIA-E findings (parenchymal and sulcal hyperintensity) was 0.88 
Page 13 of 35
American Society of Neuroimaging
Journal of Neuroimaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
(95% CI 0.79-0.93). The overall concordance between the 5 raters for PH was (ICC) 0.68; 
95% 0.51-0.81) (Table 5). The ICC for SW was 0.66 (95% CI 0.48-0.80).  
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Discussion 
 
This interobserver study confirms a high agreement in the identification of ARIA-E cases 
with less than 5% missed cases of ARIA-E per rater. In addition, it verifies a good inter-rater 
agreement for scores of sulcal hyperintensity and for the combined scores of the two findings 
used to identify ARIA-E, parenchymal and sulcal hyperintensity, using the ARIA-E scale. 
Combining the PH score with SH score increased the ICC compared to the ICC of PH alone. 
These results confirm a preliminary, smaller study in 20 patients, 10 with and 10 without 
ARIA-E
16
 and extend our findings to a larger group of less experienced raters. The range of 
mean scores confirms that the cases rated represent a wide spectrum of radiological severity. 
Sensitivity and specificity for detection of ARIA-E cases were high across all five raters. We 
consider the ARIA-E rating scale a robust and easily applicable toolreproducible scale to 
classify ARIA-E in patients undergoing scheduled MR imaging as a part of drug 
surveillance.9, 10, 13 
 
The ICC was numerically higher than in the previous study, perhaps indicating that SH may 
be more recognizable or that SH is the most common MRI imaging feature of ARIA-E.10 The 
relatively lower ICC for PH across the raters in our study is in agreement with the previous 
reports in a smaller study.15 This may reflect over or under-scoring of the largest cross-
sectional measurement of the PH, or that the multifocality of PH abnormality was not 
completely taken into account in the total scoring.  
 
The pathophysiological concept of ARIA is based on an increased vascular permeability 
associated with Aβ removal from cerebral blood vessels presumably related to amyloid 
clearance.9, 13, 17 In both ARIA-H and ARIA-E, the pathophysiology may result from leakage 
Page 15 of 35
American Society of Neuroimaging
Journal of Neuroimaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
of intravascular contents due to a shift in amyloid. In particular with ARIA-E, the leakage or 
effusion of proteinaceous fluid is believed to induce MRI changes suggestive of edema and/or 
sulcal effusions seen as high signal intensities on fluid–attenuated inversion recovery images 
(FLAIR images.
9, 11, 16
 Although swelling often accompanies SH, its detection remains more 
of a challenge due to the often subtle nature of the swelling as shown by the relatively low 
ICC compared to the other manifestations. In the current study, the ICC for swelling was 
slightly higher when compared to the previously reported value. Interestingly, the ICC of the 
combined ARIA-E score (PH+SH) is closer to the SH than the PH value. Probably, raters 
were more confident about detecting any hyperintensity, than about the individual 
contributing elements. 
 
Differentiation between sulcal and parenchymal hyperintensities as separate manifestations 
remains a challenge. The determination of the extension and boundaries for PH may be 
difficult.10 Consequently, a possible limitation of the ARIA-E rating scale, despite its 
relatively simple nature, is that it requires good neuroanatomical knowledge and its consistent 
application. We consider the scale to be best suited for experienced neuroradiologists. In 
addition, we believe that to ensure high inter-observer reliability in rating ARIA-E cases the 
sum score should be used. 
 
Several potential limitations to our study should be considered. Challenges in the assessment 
of ARIA-E stem from difficulties to detect and score ARIA-E when there are pre-existing 
vascular white matter lesions within areas of PH, or when (predominantly infratentorial) flow 
artifacts12 or impaired image quality produce false-positive findings. Figure 6 shows an 
example of the difficulties to differentiate between vascular white matter lesions and PH. 
Nonetheless, as mentioned above, sensitivity and specificity remained high across all five 
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17 
readers. A second possible limitation of our study is the fact that our dataset is still relatively 
small and relatively young. However this is the largest dataset of ARIA-E patients in which 
inter-rater reliability has been studied prospectively. Another possible limitation is that the 
frequency or ARIA-E in our sample was higher than would be expected (typically 5-20%). 
The number of 29, i.e. 39% of the total patient group, was chosen as a compromise between 
approximating the expected frequency of ARIA-E in anti-amyloid-beta (Aβ) antibody studies 
and maximization of the number of ARIA-E cases for validation.   
One more possible limitation is the fact that the ARIA-E scale has not been evaluated with 
regard tofor itstheir clinical relevance. In the current data-set many cases were only detected 
retrospectively and discussion about whether or not ARIA-E should be avoided are ongoing. 
One of the problems is defining a clinical threshold for ARIA-E has been the lack of a good 
rating scale. Currently, the ARIA-E rating scale has been used in at least 3 large phase-3 
clinical trials of amyloid-lowering therapies. Similarly, the online training module could 
easily be made available for other neuroradiologists to ensure consistency in applying the 
ARIA-E scale.    
In conclusion, the ARIA-E rating scale is a simple and robust visual rating scale that allows 
for determination of ARIA-E severity and regional categorization of the various 
manifestations. Since the amount of research in Aβ lowering immunotherapy will likely 
increase, the need for a rating instrument is apparent. We demonstrated that the MRI rating 
scale for ARIA-E is both valid and reproducible. Its application may improve the early 
identification ARIA-E. It can be completed in a relatively short period of time and may be 
used for standardized assessment to monitor medical therapy and its management in research 
studies. 
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Table 1. Characteristics of the study population. 
 
 ARIA-E No ARIA-E Total 
Number of subjects                            29 46 75 
Age (mean)(±SD)                    67.4 (8.4) 67.2 ( 8.4) 67.3 (8.4) 
MMSE (mean)(±SD)               20.6 (3.0) 20.9 (2.8) 20.8 (2.9) 
DAD (mean)(±SD)                  85.4 (15.4) 86.8 (14.0) 86.2 (14.5) 
Female, n (%)                          20 (68.9%) 26 (57.7%) 46 (62.1%) 
ApoE e4 Carriers, n (%)        22 (78.5%) 34 (77.2%) 56 (77.7%) 
ApoE e4 homozygotes           7 (25.0%) 12 (27.2%) 19 (26.3%) 
Bapineuzumab    
0.15 mg/kg, n (%)                   3 (10.3%) 10 (22.2%) 13 (17.5%) 
0.5 mg/kg, n (%)                     3 (10.3%) 14 (31.1%) 17 (22.9%) 
1.0 mg/kg, n (%)                     10 (34.4%) 13 (28.8%) 23 (31.0%) 
2.0 mg/kg, n (%)                     13 (44.8%) 8 (17.7%)         21 (28.3%) 
Values are means ±SD (standard deviation). ARIA-E (Amyloid-related imaging abnormalities 
with edema or effusion). MMSE: Mini-Mental State Examination.  DAD: Disability 
Assessment for Dementia, APOE: apolipoprotein E. n: number of patients. 
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Table 2. Overview of the ARIA-E Rating Scale 
 
Abnormality 
 
Parenchymal Hyperintensity 
Sulcal Hyperintensity 
       Swelling 
Largest cross-sectional diameter                  
 
Score 0 – none                                                                   
Score 1 - monofocal ≤2 cm 
Score 2 – multifocal ≤2cm 
Score 3 – any lesion>2 but <4cm                                 
Score 4 – any lesion ≥ 4 cm 
       Score 5 - entire lobe 
Side and region 
 
 
 
 
 
 
 
 
 
Right/Left 
Frontal 
Parietal 
Occipital 
Temporal 
Central 
       Infratentorial 
ARIA-E: Amyloid-related imaging abnormalities with edema or effusion
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Table 3. Median of ARIA-E score, parenchymal hyperintensity score, sulcal hyperintensity 
score and swelling score by rater in ARIA-E cases 
Rater 
 
ARIA-E 
PH 
SH 
SW 
1 2 3 4 5 
M           R M           R M           R M           R M          R 
12     (0-50) 
3       (0-32) 
3       (0-50) 
9       (0-50) 
7       (0-40) 
0       (0-13) 
4       (0-40) 
7       (0-37) 
12     (1-48) 
1       (0-24) 
7       (0-48) 
8       (0-48) 
5       (0-40) 
0       (0-14) 
4       (0-44) 
4       (0-44) 
8       (0-44) 
0       (0-17) 
3       (0-45) 
0       (0-26) 
 
M: Median. R: Range, ARIA-E: amyloid related imaging abnormality with edema or effusion, 
PH: parenchymal hyperintensity, SH: sulcal hyperintensity, SW: gyral swelling 
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Table 4. Sensitivity and specificity (95% confidence intervals) for patients with and without 
ARIA-E by rater 
Rater 
 
 
Sensitivity 
 
 
Specificity 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
96.6% (0.80-
1.00) 
 
97.8% 
(0.87-1.00) 
   
93.1% 
(0.76-0.99) 
 
95.7% 
(0.84-0.99) 
 
100% 
(0.85-1.00) 
 
100% 
(0.90-1.00) 
 
93.1% 
(0.75-0.99) 
 
100% 
(0.90-1.00) 
 
96.6% 
(0.80-1.00) 
 
100% 
(0.90-1.00) 
 
 
ARIA-E (Amyloid-related imaging abnormalities with edema or effusion) 
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Table 5. Interobserver agreement Intraclass correlation coefficients (ICC) and the 95 % 
confidence intervals (CI) among 5 raters 
ARIA-E (Amyloid-related imaging abnormalities with edema or effusion) 
 
 
 
 
 
 
 
 
 
 
 
MRI Findings       ICC     95% CI 
ARIA-E  (Parenchymal and sulcal hyperintensity) 
 
0.878 
 
0.790 - 0.936 
 
Sulcal hyperintensity 
 
0.915 
 
0.854 - 0.955 
Parenchymal hyperintensity 
 
0.678  
 
0.512 - 0.814 
 
Swelling 0.663 0.480 - 0.807 
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Fig 1. Average ARIA-E (Amyloid-related imaging abnormalities with edema or effusion) 
scores for the 5 raters in abnormal cases. Bars represent the average scores of the five raters of 
the maximum scores for parenchymal, sulcal hyperintensity and gyral swelling per patient of 
each rater summed across the 12 anatomic regions. The error bars represent the ranges of the 
maximum and minimum score between the 5 raters, showing that the overall variation in 
scores is relatively small between raters for the sum score.  
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Fig 2. Distribution of Sulcal hyperintensity (SH) scores for the 5 raters in the ARIA-E 
Amyloid-related imaging abnormalities with edema or effusion cases. Bars represent average 
scores of the five raters per patient summed across the 12 anatomic regions. The error bars 
represent the ranges of the maximum and minimum score between the 5 raters. 
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Fig 3. Distribution of Parenchymal hyperintensity (PH) scores for the 5 raters in the ARIA-E 
(Amyloid-related imaging abnormalities with edema or effusion) cases. Bars represent 
average scores of the five raters per patient summed across the 12 anatomic regions. The error 
bars represent the ranges of the maximum and minimum score between the 5 raters, showing 
that the overall variation in scores is larger than in average ARIA-E and sulcal hyperintensity 
(SH) scores between raters, indicating the higher level of complexity in detection of the PH. 
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Fig 4. MR images illustrate findings leading to differences in the scoring between rater 1 and 
4 for Patient 9 with widespread Amyloid-related imaging abnormalities with edema or 
effusion involving both occipital lobes. FLAIR (Fluid attenuation inversion recovery) images 
at the baseline (left side) and FLAIR images at follow up (right side) shows an extensive 
parenchymal hyperintensity (PH) in both occipital lobes. Rater 1 scored PH as 5 in both 
occipital regions and rater 4 gave a PH score of 3 for the same regions. 
Page 31 of 35
American Society of Neuroimaging
Journal of Neuroimaging
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
32 
 
Fig 5. MR images illustrate the cause of differences in the scoring between rater 1 and 2 for 
patient 7 with widespread Amyloid-related imaging abnormalities with edema or effusion 
involving both infratentorial regions. Discrepant readings for parenchymal hyperintensity 
(PH) in this patient are due to difficulty distinguishing parenchymal from sulcal 
hyperintensity (SH). The top row shows FLAIR (Fluid attenuation inversion recovery) images 
at the baseline. The lower row shows FLAIR images at the follow up with PH and SH in both 
cerebellar hemispheres. Rater 1 gave a score of 5 for PH and SH for each side (left and right) 
infratentorial, while rater 2 scored 0 for PH and 5 for SH at the same regions 
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Fig 6. Patient number 22 from the ARIA-E (Amyloid-related imaging abnormalities with 
edema or effusion) series was not recognized by only one of the raters (rater 1) This ARIA-E 
patient has substantial white matter hyperintensities  (WMH) which may visually mask an 
evolving parenchymal hyperintensities (PH). The top row shows FLAIR (Fluid attenuation 
inversion recovery) images at baseline with considerable vascular white matter lesions. The 
lower row shows follow up FLAIR images with PH distributed cortically at both partieto-
occipital lobes (arrows) 
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Fig 7. This ARIA-E (Amyloid-related imaging abnormalities with edema or effusion) patient 
presented with subtle sulcal hyperintensity (SHsulcal hyperintensity) which was recognized as 
due to ARIA-E based on parenchymal hyperintensity by three of the raters (rater 1, 3 and 5), 
but only 1 of the raters scored for SH and swelling (SW) in the left occipital lobe. The top row 
shows FLAIR (Fluid attenuation inversion recovery) images at baseline. The lower row 
shows FLAIR images at the follow up illustrating SH and SW in the left occipital lobe 
(arrows).  
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